Goodman Advisory Group’s Cytokinetics CYTK Stock Holding History

Goodman Advisory Group’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-52	Closed	-$2.86K	–	187
2025 Q3	$2.86K	Buy	+52	New	+$2.14K	﹤0.01%	167
2025 Q2	–	Sell	-600	Closed	-$24.1K	–	159
2025 Q1	$24.1K	Buy	+600	New	+$27.6K	0.01%	127
2024 Q4	–	Sell	-600	Closed	-$31.7K	–	83
2024 Q3	$31.7K	Hold	600	–	–	0.01%	130
2024 Q2	$32.5K	Hold	600	–	–	0.01%	122
2024 Q1	$42.1K	Hold	600	–	–	0.01%	101
2023 Q4	$50.1K	Hold	600	–	–	0.02%	95
2023 Q3	$17.7K	Hold	600	–	–	0.01%	116
2023 Q2	$19.6K	Hold	600	–	–	0.01%	106
2023 Q1	$21.1K	Hold	600	–	–	0.01%	96
2022 Q4	$27K	Hold	600	–	–	0.02%	89
2022 Q3	$29K	Hold	600	–	–	0.02%	88
2022 Q2	$24K	Buy	+600	New	+$24.2K	0.01%	93

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Goodman Advisory Group's CYTK Position: Q4 2025 in Review

Goodman Advisory Group sold out of Cytokinetics (CYTK) in Q4 2025, closing a stake of 52 shares — an estimated $2.86K sold.

Goodman Advisory Group first reported a position in CYTK in Q2 2022 and held it in 12 quarters. The position peaked at $50.1K in Q4 2023. 430 funds tracked by Wall St. Rank hold CYTK as of Q4 2025.

Goodman Advisory Group reported no remaining Cytokinetics position as of Q4 2025 after selling out during the quarter.
Goodman Advisory Group sold 52 Cytokinetics shares in Q4 2025, an estimated $2.86K.
Goodman Advisory Group first reported a position in Cytokinetics in Q2 2022 and held it in 12 quarters.
Goodman Advisory Group's Cytokinetics position peaked at $50.1K in Q4 2023.
430 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2025.

Based on Goodman Advisory Group's 13F filing for Q4 2025, filed 11 Feb 2026.